Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PM534 Phase I in Advanced Solid Tumors
NCT05835609Phase 1Recruiting
- Sponsor
- PharmaMar
- Start
- Dec 2022
- Primary completion
- Oct 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of PM534 in solid tumor (advanced stage), sponsored by PharmaMar. Primary endpoints: Maximum Tolerated Dose up to 46 months and Recommended Dose up to 46 months. Started Dec 2022; status: recruiting.
02
Drugs
PM534
03
Conditions
solid tumor (advanced stage)
Beyond the preview
Go deeper on NCT05835609.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05835609.